Drug Profile

H5N1 avian influenza virus vaccine - Vaxart

Alternative Names: Avian influenza vaccine - Vaxart; Bird flu vaccine - Vaxart; ND1; ND1.1

Latest Information Update: 01 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vaxart
Class Influenza A virus H5N1 vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Influenza A virus H5N1 subtype

Most Recent Events

16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (PO, Capsule)
09 Feb 2016 Vaxart plans a phase II trial for Influenza-A virus H5N1 subtype (Prevention)
01 Nov 2013 Vaxart completes a phase I trial in Influenza virus H5N1 subtype (intestinal delivery) in USA (NCT01698060)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com